# Antigenicity of key hepatitis C virus E1E2 glycoprotein neutralizing sites is genotype independent

**Authors:** Jessica L. Mimms, Ariadne Sinnis-Bourozikas, Nathaniel R. Felbinger, Nicole Frumento, Harry T. Paul, Arvind H. Patel, Zhenyong Keck, Steven K. H. Foung, Mansun Law, Richard A. Urbanowicz, Alexander W. Tarr, Jonathan K. Ball, Brian G. Pierce, Justin R. Bailey

PMC · DOI: 10.1099/jgv.0.002201 · The Journal of General Virology · 2026-01-13

## TL;DR

This study shows that the antigenic properties of HCV's E1E2 glycoprotein are not determined by the virus's genotype, which is important for vaccine development.

## Contribution

The study confirms that E1E2 antigenicity is genotype-independent using a diverse panel of HCV variants.

## Key findings

- Neutralization results for gt 2–6 E1E2 variants were similar to those of a gt 1-predominant reference panel.
- The antigenicity of E1E2 is not dictated by HCV genotype across genetically diverse variants.
- The previously published panel of 15 HCVpp accurately represents neutralization across all HCV genotypes.

## Abstract

The development of an effective prophylactic hepatitis C virus (HCV) vaccine is a priority to achieve global elimination of the virus. Accurate assessment of the neutralizing breadth of antibodies induced by vaccines and a clear understanding of the antigenic differences between viral variants included in vaccines are both critical for vaccine development. Prior studies have indicated that HCV genotypes (gts) do not dictate the sensitivity of HCV envelope glycoprotein (E1E2) variants to neutralizing antibodies. However, most of these prior studies under-sampled variants from gts 2–6. Here, we selected a genetically diverse and representative panel of gt 2–6 E1E2 variants, used them to generate HCV pseudoparticles (HCVpp), and measured neutralization of these HCVpp by neutralizing antibodies and HCV-immune plasma from persons infected with gt 1–6 viruses. We found that neutralization results obtained with this gt 2–6 panel were remarkably similar to results obtained with a previously described, antigenically diverse, gt 1-predominant reference panel of 15 HCVpp. These data confirm that, even considering genetically diverse HCV variants across gt 1–6, E1E2 antigenicity is not dictated by gt, and that the previously published panel of 15 HCVpp represents neutralization of all HCV gts with reasonable accuracy.

## Full-text entities

- **Genes:** CD81 (CD81 molecule) [NCBI Gene 975] {aka CVID6, S5.7, TAPA1, TSPAN28}, PLAT (plasminogen activator, tissue type) [NCBI Gene 5327] {aka T-PA, TPA}
- **Diseases:** death (MESH:D003643), Hepatitis (MESH:D056486), infected (MESH:D007239), end-stage liver disease (MESH:D058625), Hepatoma (MESH:D006528), cirrhosis (MESH:D005355)
- **Chemicals:** phenol (MESH:D019800), PBS (MESH:D007854), Lipofectamine (MESH:C086724), amino acids (MESH:D000596), CBH-7 (-)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606], HCV [taxon 11103], Human immunodeficiency virus 1 (no rank) [taxon 11676]
- **Cell lines:** HEK — Homo sapiens (Human), Finite cell line (CVCL_WZ56), 2-6 — Mus musculus (Mouse), Hybridoma (CVCL_A6LR), 293T — Homo sapiens (Human), Transformed cell line (CVCL_0063), Huh7 — Homo sapiens (Human), Adult hepatocellular carcinoma, Cancer cell line (CVCL_0336), 3.Luc — Mus musculus (Mouse), Transformed cell line (CVCL_A7FZ), pNL4 — Homo sapiens (Human), Ataxia telangiectasia syndrome, Finite cell line (CVCL_F083), CD81ko — Homo sapiens (Human), Xeroderma pigmentosum, complementation group G, Finite cell line (CVCL_ZS94)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12798819/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12798819/full.md

## References

41 references — full list in the complete paper: https://tomesphere.com/paper/PMC12798819/full.md

---
Source: https://tomesphere.com/paper/PMC12798819